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Abstract
Objective To compare vulvovaginal swabs with endocervical swabs as
optimal diagnostic sample for detection of Chlamydia trachomatis
infection.
Design A diagnostic test study.
Setting An urban sexual health centre.
Participants 3973 women aged ≥16 years requesting testing for sexually
transmitted infections.
Interventions Participants took a vulvovaginal swab before routine
examination, and clinicians took an endocervical swab during
examination.
Main outcomemeasureDiagnosis of chlamydia infection with samples
analysed using the Aptima Combo-2 assay; positive results confirmed
with the Aptima CT assay.
Results Of the 3973 participants, 410 (10.3%) were infected with C
trachomatis. Infected women were significantly younger (22 v 25 years,
P<0.0001) and more likely to have symptoms suggestive of a bacterial
sexually transmitted infection (53% v 41%, odds ratio 1.63 (95% CI 1.30
to 2.04)), be a contact of someone with a sexually transmitted infection
(25% v 5%, odds ratio 6.18 (4.61 to 8.30)), clinically diagnosed with
cervicitis (17% v 4%, odds ratio 4.92 (3.50 to 6.91)), and have pelvic
inflammatory disease (9% v 3%, odds ratio 2.85 (1.87 to 4.33)). When
women co-infected with gonorrhoea were included in the analysis, there
was an association with mixed ethnicity (10% v 7%, odds ratio 1.53 (1.07
to 2.17)); but when those with gonorrhoea were removed, women of
white ethnicity were significantly more likely to have chlamydia (85% v
80%, odds ratio 1.40 (1.03 to 1.91)). On analysis of complete paired
results, vulvovaginal swabs were significantly more sensitive than
endocervical swabs (97% (95% CI 95% to 98%) v 88% (85% to 91%),
P<0.00001); corresponding specificities were 99.9% and 100%. In women
with symptoms suggestive of a bacterial sexually transmitted infection,
vulvovaginal swabs were significantly more sensitive than endocervical
swabs (97% (93% to 98%) v 88% (83% to 92%), P=0.0008), as they
were in women without symptoms (97% (94% to 99%) v 89% (84% to
93%), P=0.002).
Conclusions Vulvovaginal swabs are significantly better than
endocervical swabs at detecting chlamydia in women with and without
symptoms suggestive of sexually transmitted infections. In those with
symptoms, using endocervical samples rather than vulvovaginal swabs
would have missed 9% of infections, or 1 in every 11 cases of chlamydia.
Trial registration ISRCTN42867448.
Introduction
Chlamydia is the most common sexually transmitted infection
diagnosed and treated in the United Kingdom,1with the highest
rates in young people under the age of 25 years. It is often
asymptomatic but can have serious sequelae if left untreated.
In women, ascending infection causes pelvic inflammatory
disease with potential complications of infertility and ectopic
pregnancy. Chlamydia trachomatis can infect the urethra or
endocervix, or both. Studies looking at sites of chlamydia
infection in women found chlamydia present in both urethra
and endocervix in 73-76%, endocervix only in 15-16%, and
urethra only in 10-11%.2 3 The optimal diagnostic sample must
be able to detect the maximum number of infected people. Also,
as up to 70% of infected females can be asymptomatic, it is
important that diagnostic tests have good sensitivity and
specificity at detecting chlamydia in women both with and
without symptoms.
Nucleic acid amplification tests are the “gold standard” for C
trachomatis detection because of their high sensitivity and
specificity. With these tests, numerous studies have shown that
non-invasively obtained samples are as accurate as those
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obtained from the urethra and endocervix.4 For women without
symptoms, non-invasive samples eliminate some of the barriers
to screening for chlamydia as they require no examination and
are clearly preferred by patients.5 6 The non-invasive samples
used in women are first-catch urine samples or self collected
vulvovaginal swabs. Evidence suggests that self collected
vulvovaginal swabs have the better sensitivity, probably because
they collect more material from the two potential sites of
infection.7-12
The Gen-Probe Aptima Combo-2 assay uses transcription
mediated amplification and automatically tests for both
chlamydia and gonorrhoea on each sample at no extra cost
compared with testing for one pathogen. However, only one
swab can be included in each assay tube. Before switching to
Aptima Combo-2, our practice in testing women who needed
an examination because they had symptoms had been to place
swabs from both the urethra and endocervix in the same
transport medium for analysis by our previous assay. On
transferring to the Aptima Combo-2 assay, we needed to choose
between endocervical and vulvovaginal sampling.Most studies
have shown that the two samples are equivalent,4 7 10 13-19
suggesting that, when a woman is undergoing an examination,
an endocervical swab would be preferable on the assumption
that it is superior for detecting low chlamydial load in the
endocervix (which if missed could leave women at risk of
ascending infection). However, one study found vulvovaginal
swabs to be significantly more sensitive than endocervical swabs
(81% v 65%), although the authors commented that the
sensitivity of the endocervical swabs was lower than in
previously published studies.9 Hence, it remains unclear which
is the optimum sample in women requiring examination.
As part of a study comparing self taken vulvovaginal swabs
with clinician taken urethral and endocervical swabs for the
detection of gonorrhoea,20 we were able to evaluate the
diagnostic accuracy of self taken vulvovaginal swabs versus
clinician taken endocervical swabs for the detection of
chlamydia, using the Aptima Combo-2 assay.
Methods
The full methods for the study are described elsewhere.20Women
aged ≥16 years who presented to the Centre for Sexual Health
at Leeds for a new visit were invited to participate. Exclusion
criteria were having taken antibiotics in the preceding 28 days
and being unable or unwilling to take a vulvovaginal swab or
to have the standard examination and swabs performed by a
clinician. We collected details of the women’s age, ethnicity,
history of sexually transmitted infections, and being in contact
with a sexually transmitted infection. During themedical history,
symptoms in keeping with a bacterial sexually transmitted
infection (vaginal discharge, dysuria, intermenstrual or postcoital
bleeding, deep dyspareunia, and lower abdominal pain) were
recorded. During the examination the presence of cervicitis and
pain or tenderness on bimanual pelvic examination in keeping
with a clinical diagnosis of pelvic inflammatory disease were
noted.
The self taken vulvovaginal swabwas taken before examination.
The women were then examined, and the clinician took an
endocervical sample. Consequently, each woman had samples
for chlamydia taken from two different sites, the vulvovagina
and endocervix, and these were both analysed forC trachomatis
by means of the Aptima Combo-2 assay. The assays were
performed at the Department of Microbiology by accredited
laboratory staff. The vulvovaginal swabs and endocervical
samples were assayed according to the manufacturer’s
instructions (Gen-Probe, San Diego CA, USA). The assay
employs transcription mediated amplification technology in
which rRNA target molecules from C trachomatis are isolated
and specific regions are amplified by using a separate capture
oligomer and a unique set of primers.
The cut-off values for the chlamydia results were determined
by Tigris software for each run. The results of the initial Aptima
Combo-2 assay were therefore positive, equivocal, or negative
for C trachomatis. Positive or equivocal tests were further
analysed using the Aptima CT mono-specific platform assay,
which has a different target to the Aptima Combo-2. The
samples were only reported as clinically positive if confirmed
as positive by the Aptima CT. This algorithm of repeat testing
for confirmation is currently the suggested national standard
operating procedure in England.21 A positive or equivocal
Aptima Combo-2 assay unconfirmed by Aptima CT was
reported as indeterminate. A patient was considered to have C
trachomatis infection if an endocervical or vulvovaginal swab
gave at least one positive Aptima Combo-2 test result that was
confirmed by the Aptima CT mono-specific platform test. As
the cut-off values for the chlamydia results were determined by
the Tigris software for each run, the results of these could not
be influenced by the laboratory staff.
Statistical analysis
We used theMannWhitney U test to determine any associations
between the presence of C trachomatis and age and the χ2 test
to determine associations between C trachomatis and the
categorical variables. The overall sensitivity, specificity, positive
predictive value, and negative predictive value were calculated
for the Aptima Combo-2 assay with an endocervical swab and
the Aptima Combo-2 assay with a vulvovaginal swab. These
analyses were also performed for women with and without
symptoms. Any differences between sensitivities were compared
using McNamar’s test on paired samples.
Results
Participants
Full demographic data and infection status were available for
3973 women recruited by 42 different clinicians, both doctors
and nurses, between March 2009 and January 2010. The
participants’ mean age was 25 years (range 16–59), and self
reported ethnicity was 80% white (n=3171), 9% black (362),
7% mixed (297), and 4% other (143). A previous diagnosis of
sexually transmitted infection was reported in 1478 (37%), and
292 (7%) reported contact with a partner recently diagnosed
with a sexually transmitted infection. At least one symptom
suggestive of a bacterial sexually transmitted infection was
reported by 1671 (42%) of the participants. A clinical diagnosis
of cervicitis was made in 218 (5%), and 169 (4%) had a clinical
diagnosis of pelvic inflammatory disease.
In all, 410 of the 3973 women had C trachomatis infection
(prevalence 10.3%). The factors associated with having
chlamydia are shown in table 1⇓. Fifty five (13.4%) of the
women with chlamydia were co-infected with Neisseria
gonorrhoeae, leaving 355 women with chlamydia but no
gonorrhoea. In total, 100 of the 3973 womenwere infected with
gonorrhoea (prevalence 2.5%), leaving 3518 women (88.5%)
who were chlamydia and gonorrhoea negative. As gonorrhoea
is more likely to cause symptoms and signs suggestive of a
bacterial sexually transmitted infection, the data have been
analysed including and excluding the women infected with
gonorrhoea (table 1⇓).
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In the whole cohort, women with chlamydia, were significantly
more likely to be of mixed ethnicity, to be younger, to have
symptoms suggestive of a bacterial sexually transmitted
infection, to be a contact of a sexually transmitted infection,
and to be clinically diagnosed as having cervicitis and pelvic
inflammatory disease, irrespective of whether they were
co-infected with gonorrhoea. However, when those infected
with gonorrhoea are removed, women of white ethnicity were
significantly more likely to have chlamydia compared with
non-white women. Women of “other” ethnic origin were
significantly less likely to have chlamydia compared with white
women irrespective of whether they were co-infected with
gonorrhoea.
Test sensitivities and specificities
Some test results were missing because of problems with sample
collection: 29 of the endocervical swabs taken by clinicians
could not be processed because of staff errors in labelling, and
77 of the self taken vulvovaginal swabs could not be processed
because of participant errors with the sample tube or staff errors
in labelling. This meant that 106 (2.7%) of the women recruited
had to be removed before statistical analysis with the paired
McNemar’s test. Table 2⇓ shows the test results for the 3867
women with complete paired results. Of these, 396 (10.2%)
were positive for chlamydia. The sensitivities of the clinician
taken endocervical swabs and self taken vulvovaginal swabs
were 88% and 97% respectively (P<0.00001).
Only 10 (0.13%) of the 7734 chlamydia samples were reported
as indeterminate, six vulvovaginal swabs and four endocervical
swabs. Of the six indeterminate vulvovaginal swab results, three
were positive with the Aptima Combo-2 assay but unconfirmed
by the Aptima CT assay. Two of these were classified as false
positives as the respective endocervical results were negative,
and one was classified as a true positive as the respective
endocervical result was positive. The remaining three
indeterminate vulvovaginal swab results were equivocal with
Aptima Combo-2 and unconfirmed with Aptima CT. Two of
these had negative endocervical results and so were classified
as true negatives, and the other had a positive endocervical result
and was classified as a false negative. Of the four endocervical
swabs that gave indeterminate results, two had positive Aptima
Combo-2 results that were unconfirmed by Aptima CT. As the
respective vulvovaginal swabs were positive, they were
classified as true positives. The other two had equivocal Aptima
Combo-2 results that were unconfirmed by Aptima CT. As the
vulvovaginal swabs were negative, they were classified as true
negatives. Table 3⇓ shows the sensitivities, specificities, positive
predictive values, and negative predictive values for the Aptima
Combo-2 assay.
Diagnostic accuracy of tests in women with
and without symptoms
At least one symptom suggestive of a bacterial sexually
transmitted infection was reported by 1634 (42%) of the
participants with complete paired results. Of these, 213 (13%)
women were infected with chlamydia. The sensitivities of
clinician taken endocervical swabs and self taken vulvovaginal
swabs were 88% (187/213) and 97% (206/213) respectively
(P=0.0008).
There were 2233 (58%) women who did not have symptoms
suggestive of a bacterial sexually transmitted infection, 183
(8%) of whom were infected with chlamydia. The sensitivities
of clinician taken endocervical swabs and self taken
vulvovaginal swabs were 89% (163/183) and 97% (178/183)
respectively (P=0.0025).
There were 1347 women (35%) who would have been suitable
for an “asymptomatic screen”—that is, they did not have any
symptoms suggestive of a bacterial sexually transmitted
infection and did not require examination for any other reason
(such as symptoms of genital skin pathology). Of these, 76
(5.6%) had chlamydia infection. The sensitivities of clinician
taken endocervical swabs and self taken vulvovaginal swabs
were 89% (68/76) and 95% (72/76) respectively (P=0.27).
Discussion
This is the first study to show that vulvovaginal swabs analysed
by Aptima Combo-2 are significantly better at detecting C
trachomatis than endocervical swabs in womenwith andwithout
symptoms of a sexually transmitted infection. The overall
sensitivities were 97% for vulvovaginal swabs and 88% for
endocervical swabs, meaning that endocervical swabs diagnosed
9% fewer infections, missing one in every 11 cases of
chlamydia. One previous study also found vulvovaginal swabs
to be significantly more sensitive than endocervical swabs (at
81% versus 65% respectively), but the authors commented that
the sensitivity of the endocervical swabs was lower than in
previously published studies, which may have been due to a
different laboratory being used for their analysis.9 Some other
studies have reported higher (but non-significant) chlamydia
sensitivities with vulvovaginal swabs compared with
endocervical swabs.
We have identified 11 published papers where there are
comparisons between vulvovaginal swabs and endocervical
swabs using nucleic acid amplification tests for the detection
of chlamydia.7 9-11 13-19 One included a comparison using two
different nucleic acid amplification tests, making 12 comparisons
in total.19 Two of the comparisons found a higher sensitivity
with the endocervical swabs, with differences of 1.8%15 and
0.6%,11 whereas 10 found a higher sensitivity with the
vulvovaginal swabs, with a median of 5.1% difference and a
range of 1.2–16.0%.7 9 10 13 14 16-19 Exact data were available in
nine of the 11 papers.9-11 13-18 Combining the results, the
endocervical swabs diagnosed chlamydia in 772/892 (86.5%)
and the vulvovaginal swabs diagnosed chlamydia in 824/886
(93.0%), a difference of 6.5%. As reported in other studies, we
found excellent specificity using both the endocervical swabs
(100%) and the vulvovaginal swabs (99.9%) for the detection
of chlamydia with the Aptima Combo-2 assay.19 22
We think the difference in sensitivity between endocervical
swabs and vulvovaginal swabs is probably due tomissed urethral
infections when the endocervical site alone is sampled. This
theory is supported by a study that investigated use of using
first-catch urine samples in addition to endocervical swabs; it
found that endocervical swabs tested by Aptima Combo-2
detected 99.4% of cervical C trachomatis infections but only
92.1% of the total C trachomatis infections because some were
detected only with first-catch urine. This reduction in sensitivity
was greater when testing for chlamydia than for gonorrhoea.22
Also, a study comparing sensitivities of endocervical swabs,
vulvovaginal swabs, and first-catch urine samples, separately
or in combination, for the detection of chlamydia found the
separate endocervical swab, vulvovaginal swab, and first-catch
urine samples detected 65%, 81%, and 72% respectively,
whereas the endocervical swab plus first-catch urine detected
86%, the endocervical and vulvovaginal swabs detected 91%,
and the vulvovaginal swab plus first-catch urine detected 94%.9
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Implications of study results
The higher chlamydia diagnostic sensitivity with vulvovaginal
swabs in our study was seen in all women irrespective of
whether they had symptoms suggestive of a bacterial sexually
transmitted infection. In those who would not routinely require
a genital examination, endocervical swabs and vulvovaginal
swabs were equivalent. Our study therefore confirms the
previous evidence that in women without symptoms, and for
those who do not require a speculum examination, the sample
of choice is a self taken vulvovaginal swab, which is an
appropriate sample to test for both chlamydia and gonorrhoea.20
In women with symptoms the sensitivity of chlamydia detection
by means of vulvovaginal swabs was significantly higher than
for endocervical swabs (97% versus 88%). Using endocervical
samples rather than vulvovaginal swabs would have missed 9%
of infections, or one in every 11 cases of chlamydia. These
findings give a clear indication that the best single sample for
chlamydia detection in women with symptoms is the
vulvovaginal swab. Therefore, in womenwith symptoms, where
a speculum examination would be normal practice, we
recommend either a self taken vulvovaginal swab before the
examination or a clinician taken vulvovaginal swab before the
speculum insertion. These have been shown to be equivalent in
sensitivity,10 but the clinician taken sample has the advantage
that patient errors in collection are eliminated.
The associations of chlamydia infection with younger age and
mixed ethnicity, and decreased likelihood in women of “other”
ethnicity are in keeping with data from the National Chlamydia
Screening Programme (NCSP), which found that chlamydia
disproportionately affects young adults and black or mixed
ethnic groups.23However, some women with chlamydia (13.4%
in our study) are co-infected with gonorrhoea, which is also
associated with black or mixed ethnicity.20 Interestingly when
those with gonorrhoea were removed from our data, white
women were significantly more likely to have chlamydia
compared with non-white women. Our findings suggest that
when assessing any association between ethnicity and chlamydia
infection, gonorrhoea is a confounding factor. The NCSP data
do not identify those with and without gonorrhoea, as chlamydia
status is tested but not necessarily gonorrhoea status. From our
study findings, we suggest white ethnicity should be considered
as a risk factor for chlamydia infection in the UK.
Strengths and limitations of study
The strengths of our study include its large number of
participants with 42 different clinicians collecting the
samples—as such, it is reflective of real clinical situations. The
population attending the Centre for Sexual Health at Leeds is
similar to many other clinic populations, both in the UK and in
other countries, meaning our findings are widely applicable.
The limitations are that, although there were a large number of
participants, this was a single centre study. The order of the
samples was not randomised or rotated. The self taken
vulvovaginal swab was collected before the clinician taken
endocervical swab. In other published studies comparing
vulvovaginal swabs with endocervical samples, the vulvovaginal
swab was performed first, before the insertion of a vaginal
speculum.7 9 10 14 16-19 As the sites for these samples are different,
there is no reason to suspect that taking the vulvovaginal swab
would affect the sensitivity of the endocervical sample.
However, as part of the diagnostic comparisons for gonorrhoea
in this study,20 all participants had an endocervical swab taken
for gonorrhoea culture, which was performed before the
endocervical swab for Aptima Combo-2 assay in view of the
reduced sensitivity of culture.
It could be argued that taking the endocervical culture sample
first reduces the sensitivity of the endocervical sample for
nucleic acid amplification tests, which might account for the
lower sensitivity in our endocervical samples compared with
the vulvovaginal swabs. We believe this is unlikely, as a
comparison of endocervical swabs and cytobrushes (using a
less sensitive test than a nucleic acid amplification test) showed
no difference in the rate of detection of C trachomatis
irrespective of the order in which they were performed.24
Further limitations are that negative Aptima Combo-2 tests were
not repeated, so we could have missed some false negative
results. This is unlikely, however, as each participant had two
different samples analysed for chlamydia. As we assessed only
one nucleic acid amplification test, our results cannot necessarily
be extrapolated to other such tests. The sensitivity and specificity
of different nucleic acid amplification tests for chlamydia
detection can vary, as reported in a systematic review.4
Conclusions
The optimal diagnostic sample must be able to detect the
maximum number of infected people, and we found that
vulvovaginal swabs analysed byAptimaCombo-2 for chlamydia
infection were significantly more sensitive than endocervical
swabs, which missed 9% of cases in routine clinical practice.
Therefore, in women who do not require a speculum
examination the sample of choice is a self taken vulvovaginal
swab. This has benefits for the patient in that a genital
examination is avoided, and it has health economic benefits in
that clinician time and equipment use is reduced. For women
with symptoms, we would recommend either a self taken
vulvovaginal swab before the examination or a clinician taken
vulvovaginal swab before speculum insertion.
Contributors: JDW conceived the study and wrote the protocol with
assistance from MHW. CMWS, SAS, and JDW recruited participants,
and RAB, SDS, andMHWperformed themicrobiological testing. CMWS
and SAS coordinated the study and with JDW produced the database
and analysed the data. All authors contributed to writing the paper and
had full access to all of the data in the study and can take responsibility
for the integrity of the data and the accuracy of the data analysis. JDW
and MHW are the guarantors for the study.
Funding: No specific funding for the study.
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: extra diagnostic
reagents and equipment needed for the study were provided by
Gen-Probe; no financial relationships with any organisations that might
have an interest in the submitted work in the previous three years; no
other relationships or activities that could appear to have influenced the
submitted work.
Ethical approval: Leeds (East) Research Ethics Committee granted
ethical approval for the study. All participants gave informed consent
before taking part in the study.
Data sharing: No additional data available
1 Health Protection Agency. Sexually transmitted infections in England. Health Protection
Report 2011;5(24). www.hpa.org.uk/hpr/archives/2011/hpr2411.pdf.
2 Buimer M, van Doornum GJJ, Ching S, Peerbooms PG, Plier PK, Ram D, et al. Detection
of Chlamydia trachomatis and Neisseria gonorrhoeae by ligase chain reaction-based
assays with clinical specimens from various sites: implications for diagnostic testing and
screening. J Clin Microbiol 1996;34:2395-400.
3 Hay PE, Thomas BJ, Horner PJ, MacLeod E, Renton AM, Taylor-Robinson D. Chlamydia
trachomatis in women: the more you look, the more you find. Genitourin Med
1994;70:97-100.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e8013 doi: 10.1136/bmj.e8013 (Published 12 December 2012) Page 4 of 8
RESEARCH
What is already known on this topic
The optimal diagnostic sample for Chlamydia trachomatis detection should detect the maximum number of infected people
In women without symptoms the sample of choice is a self taken vulvovaginal swab, but it is not clear whether a vulvovaginal swab or
an endocervical swab is the optimum sample in women with symptoms requiring speculum examination
What this study adds
In this study of women attending a sexual health centre vulvovaginal swabs were significantly better at detecting chlamydia infection
than endocervical swabs among women with symptoms of a sexually transmitted infection
In these cases, using endocervical samples rather than vulvovaginal swabs would have missed 9% of infections, or 1 in 11 cases of
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Tables
Table 1| Factors associated with Chlamydia trachomatis infection among 3973 women recruited at a sexual health centre. Values are
numbers (percentages) of women unless stated otherwise
P value*Odds ratio (95%CI) for infection*
Chlamydia
prevalence (%)
Negative for chlamydia
(n=3563)
Positive for chlamydia
(n=410)
Including women infected with Neisseria gonorrhoeae (n=3973)
<0.000110.32522Mean age (years)
<0.00011.65 (1.34 to 2.03)13.01453 (41)218 (53)Symptoms of STI
0.910.98 (0.79 to 1.22)10.21327 (37)151 (37)Previous STI
<0.00016.10 (4.63 to 8.03)35.6188 (5)104 (25)Contact of person with STI
<0.00015.48 (4.01 to 7.48)34.9142 (4)76 (19)Cervicitis
<0.00012.88 (1.95 to 4.23)23.7129 (4)40 (10)Pelvic inflammatory disease
Ethnicity:
0.351.15 (0.87 to 1.50)10.62836 (80)335 (82)White
0.210.77 (0.51 to 1.15)8.3332 (9)30 (7)Black
0.0181.53 (1.07 to 2.17)14.5254 (7)43 (10)Mixed
0.00060.12 (0.02 to 0.49)1.4141 (4)2 (<1)Other
Excluding women infected with Neisseria gonorrhoeae (n=3873)
3518355No of women
<0.00019.22522Mean age (years)
<0.00011.63 (1.30 to 2.04)11.61427 (41)187 (53)Symptoms of STI
0.980.99 (0.78 to 1.25)9.11302 (37)130 (37)Previous STI
<0.00016.18 (4.61 to 8.30)33.1178 (5)88 (25)Contact of person with STI
<0.00014.92 (3.50 to 6.91)30.1137 (4)59 (17)Cervicitis
<0.00012.85 (1.87 to 4.33)21.3122 (3)33 (9)Pelvic inflammatory disease
Ethnicity†:
0.031.40 (1.03 to 1.91)9.72812 (80)301 (85)White
0.160.73 (0.46 to 1.13)7.2322 (9)25 (7)Black
0.961.03 (0.67 to 1.59)10.0244 (7)27 (7)Mixed
0.0020.13 (0.02 to 0.54)1.4140 (4)2 (<1)Other
STI=sexually transmitted infection.
*Mean ages compared by Mann-Whitney U test, all other factors compared by Pearson’s χ2 test with Yates correction.
†White women compared with non-white groups combined. Non-white groups compared with white women.
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Table 2| Comparison of self taken vulvovaginal swabs with clinician taken endocervical swabs as diagnostic samples for detection of
Chlamydia trachomatis infection among 3867 women recruited at a sexual health centre. Values are numbers of women unless stated
otherwise
P value*% Sensitivity (95% CI)Total
Chlamydia infection status
NegativePositive
Whole cohort
<0.0000188 (85 to 91)Endocervical swab:
3500350Positive
3517347146Negative
38673471396Total
97 (95 to 98)Vulvovaginal swab:
3862384Positive
3481346912Negative
38673471396Total
Women with symptoms suggestive of bacterial sexually transmitted infection
0.000888 (83 to 92)Endocervical swab:
1870187Positive
1447142126Negative
16341421213Total
97 (93 to 98)Vulvovaginal swab:
2071206Positive
142714207Negative
16341421213Total
Women without symptoms suggestive of bacterial sexually transmitted infection
0.002589 (84 to 93)Endocervical swab:
1630163Positive
2070205020Negative
22332050183Total
97 (94 to 99)Vulvovaginal swab:
1791178Positive
205420495Negative
22332050183Total
Women suitable for asymptomatic screen
0.266889 (81 to 95)Endocervical swab:
68068Positive
127912718Negative
1347127176Total
95 (87 to 98)Vulvovaginal swab:
73172Positive
127412704Negative
1347127176Total
*Endocervical swab compared with vulvovaginal swab.
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Table 3| Sensitivities, specificities, and positive and negative predictive values of testing for Chlamydia trachomatis infection with self
taken vulvovaginal swabs or with clinician taken endocervical swabs as diagnostic samples among 3867 women recruited at a sexual
health centre. Values are percentages
Predictive value
Specificity (95% CI)Sensitivity (95% CI) NegativePositive
Whole cohort
98.7100100 (99.9 to 100)88 (85 to 91)Endocervical swab
99.799.599.9 (99.8 to 100)97 (95 to 98)Vulvovaginal swab
Women with symptoms suggestive of bacterial sexually transmitted infection
98.2100100 (99.7 to 100)88 (83 to 92)Endocervical swab
99.599.599.9 (99.6 to 100)97 (93 to 98)Vulvovaginal swab
Women without symptoms suggestive of bacterial sexually transmitted infection
99.0100100 (99.8 to 100)89 (84 to 93)Endocervical swab
99.899.499.9 (99.7 to 100)97 (94 to 99)Vulvovaginal swab
Women suitable for asymptomatic screen
99.4100100 (99.7 to 100)89 (81 to 95)Endocervical swab
99.798.699.9 (99.6 to 100)95 (87 to 98)Vulvovaginal swab
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